Hyperion Defi to Report Second Quarter 2025 Results on Wednesday, August 13, 2025
Rhea-AI Summary
Hyperion Defi (NASDAQ: HYPD), a pioneer in integrating decentralized finance with traditional corporate treasury strategies and the first U.S. public company to build a strategic treasury around the HYPE token, has scheduled its Q2 2025 earnings conference call for Wednesday, August 13, 2025, at 4:30 p.m. ET.
Investors can join via phone using the conference code 13754799 or through a live webcast available on the company's website. The company also reminds shareholders to vote before the Annual General Meeting scheduled for Monday, August 18th.
Positive
- None.
Negative
- None.
News Market Reaction – HYPD
On the day this news was published, HYPD gained 4.96%, reflecting a moderate positive market reaction. Argus tracked a peak move of +35.0% during that session. Argus tracked a trough of -3.3% from its starting point during tracking. Our momentum scanner triggered 63 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $45.37M at that time. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.
Data tracked by StockTitan Argus on the day of publication.
Company to host an investor conference call and webcast at 4:30 pm ET
NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Hyperion Defi, Inc. (NASDAQ: HYPD), the first U.S. public company to build a strategic treasury around the HYPE token and a pioneer in integrating decentralized finance with traditional corporate treasury strategies, will host its second quarter 2025 earnings call on Wednesday, August 13, 2025, at 4:30 p.m. to review the financial and operating results.
Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international) with the conference code 13754799. A live webcast of the conference call will also be available here as well as on the investor relations page of the Company's corporate website at Hyperion Defi.
To access the Call me™ feature, which avoids having to wait for an operator, click here.
After the live webcast, the event will be archived on Hyperion Defi’s website for one year.
Annual Meeting
The management team of Hyperion DeFi reminds investors to vote ahead of the Company’s upcoming Annual General Meeting, which is scheduled for Monday, August 18th.
About Hyperion DeFi, Inc.
Hyperion DeFi, Inc. is the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid’s native token, HYPE. The Company is focused on providing its shareholders with simplified access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world. Shareholders benefit from a gradually compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its unique on-chain utility.
Hyperion DeFi is also completing development of its Optejet User Filled Device (UFD) that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in better outcomes for patients and providers. The company is currently exploring strategic options for this technology.
For more information, please visit Hyperiondefi.com.
Forward Looking Statements
Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements, our future activities or other future events or conditions, including the estimated market opportunities for our platform technology, the viability of, and risks associated with, our cryptocurrency treasury strategy, the clinical trials that may be necessary in connection with the clearance of the Optejet UFD, and the timing for sales growth of our approved products. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.
In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the potential advantages of our products, and platform technology; the rate and degree of market acceptance and clinical utility of our products; our estimates regarding the potential market opportunity for our products; reliance on third parties to develop and commercialize our products; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our products; intellectual property risks; changes in legal, regulatory, legislative and geopolitical environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products and product candidates; our competitive position; our ability to raise additional funds to maintain our business operations and to make payments on our debt obligations as and when necessary; and the risks of our cryptocurrency strategy as detailed in our Current Report on Form 8-K filed on June 27, 2025.
Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Hyperion DeFi does not undertake any obligation to update any forward-looking statements.
Hyperion DeFi, Inc. Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
FAQ
When is Hyperion Defi (HYPD) reporting Q2 2025 earnings?
How can investors join Hyperion Defi's Q2 2025 earnings call?
When is Hyperion Defi's 2025 Annual General Meeting?
Where can I access the replay of Hyperion Defi's Q2 2025 earnings call?
